Immunisation and multi-dose vials

Iain B. Gosbell; Thomas Gottlieb; Alison M. Kesson; Jeffrey J. Post; Dominic E. Dwyer

doi:10.1016/j.vaccine.2010.07.052

Immunisation and multi-dose vials

Iain B. Gosbell
, Thomas Gottlieb
, Alison M. Kesson
, Jeffrey J. Post
, Dominic E. Dwyer

School of Medicine

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

The current novel H1N1 09 influenza virus pandemic has resulted in 37,722 diagnoses, 4992 hospitalisations, and 191 deaths in Australia as of 11 June 2010. A mass immunisation campaign has commenced using a multi-dose vial formulation to assist rapid deployment. However, in the past multi-dose vials have been associated with transmission of infective agents. Having the vaccine in single-dose vials with a lesser risk of transmission of infection but increased delay in implementation and increased cost needs to be weighed against the imperative to vaccinate the population against pandemic H1N1 09 influenza virus. This article reviews the infectious risks associated with multi-dose vials.

Original language	English
Pages (from-to)	6556-6561
Number of pages	6
Journal	Vaccine
Volume	28
Issue number	40
DOIs	https://doi.org/10.1016/j.vaccine.2010.07.052
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.vaccine.2010.07.052

Cite this

@article{030516e07369426eb23efea80d2401c3,

title = "Immunisation and multi-dose vials",

abstract = "The current novel H1N1 09 influenza virus pandemic has resulted in 37,722 diagnoses, 4992 hospitalisations, and 191 deaths in Australia as of 11 June 2010. A mass immunisation campaign has commenced using a multi-dose vial formulation to assist rapid deployment. However, in the past multi-dose vials have been associated with transmission of infective agents. Having the vaccine in single-dose vials with a lesser risk of transmission of infection but increased delay in implementation and increased cost needs to be weighed against the imperative to vaccinate the population against pandemic H1N1 09 influenza virus. This article reviews the infectious risks associated with multi-dose vials.",

author = "Gosbell, \{Iain B.\} and Thomas Gottlieb and Kesson, \{Alison M.\} and Post, \{Jeffrey J.\} and Dwyer, \{Dominic E.\}",

year = "2010",

doi = "10.1016/j.vaccine.2010.07.052",

language = "English",

volume = "28",

pages = "6556--6561",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "40",

}

TY - JOUR

T1 - Immunisation and multi-dose vials

AU - Gosbell, Iain B.

AU - Gottlieb, Thomas

AU - Kesson, Alison M.

AU - Post, Jeffrey J.

AU - Dwyer, Dominic E.

PY - 2010

Y1 - 2010

N2 - The current novel H1N1 09 influenza virus pandemic has resulted in 37,722 diagnoses, 4992 hospitalisations, and 191 deaths in Australia as of 11 June 2010. A mass immunisation campaign has commenced using a multi-dose vial formulation to assist rapid deployment. However, in the past multi-dose vials have been associated with transmission of infective agents. Having the vaccine in single-dose vials with a lesser risk of transmission of infection but increased delay in implementation and increased cost needs to be weighed against the imperative to vaccinate the population against pandemic H1N1 09 influenza virus. This article reviews the infectious risks associated with multi-dose vials.

AB - The current novel H1N1 09 influenza virus pandemic has resulted in 37,722 diagnoses, 4992 hospitalisations, and 191 deaths in Australia as of 11 June 2010. A mass immunisation campaign has commenced using a multi-dose vial formulation to assist rapid deployment. However, in the past multi-dose vials have been associated with transmission of infective agents. Having the vaccine in single-dose vials with a lesser risk of transmission of infection but increased delay in implementation and increased cost needs to be weighed against the imperative to vaccinate the population against pandemic H1N1 09 influenza virus. This article reviews the infectious risks associated with multi-dose vials.

UR - http://handle.uws.edu.au:8081/1959.7/554192

U2 - 10.1016/j.vaccine.2010.07.052

DO - 10.1016/j.vaccine.2010.07.052

M3 - Article

C2 - 20678588

SN - 0264-410X

VL - 28

SP - 6556

EP - 6561

JO - Vaccine

JF - Vaccine

IS - 40

ER -

Immunisation and multi-dose vials

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this